J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

 
• By Jessica Merrill
  
pillar
J&J outlined a broad development plan for nipocalimab, which it hopes will be a new pillar brand • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immunological

More from Therapeutic Category